ReviewNature reviews. Disease primers2023
Chikungunya fever.
Review in Nature reviews. Disease primers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 183 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
183 citing papers in PubMed, 1 synthesis or guideline pooled it, 229 citations in OpenAlex.
- A bibliometric analysis of vaccine research on Chikungunya virus: contributors, trends, and emerging frontiers.Frontiers in immunology · 2025Pooled it
- A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults.The Journal of infectious diseases · 2026Trial
- Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial.Nature medicine · 2026Trial
- Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages.Emerging microbes & infections · 2025Trial
- A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.Journal of travel medicine · 2024Trial
- Assessing the Vector Competence for Chikungunya Virus in Mosquitoes.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Research progress on the role of host factors in Chikungunya virus infection and intervention strategies.Virulence · 2026Review
- Rapid differentiation of VLA1553 and wild-type ECSA chikungunya strains in the context of an IXCHIQ vaccination campaign.Emerging microbes & infections · 2026Article
- Global resurgence of Chikungunya virus: outbreak drivers and emerging solutions.Emerging microbes & infections · 2026Review
- An ECSA-lineage chikungunya outbreak in Foshan, China: age-stratified clinical and virological profiles.Emerging microbes & infections · 2026Article
- Characterization of the clinical forms of chronic chikungunya: an observational cohort study in Rio de Janeiro.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Observational
- Article
- Ross River virus transmission, infection, and disease: two and a half decades of research progress-an updated cross-disciplinary review.Clinical microbiology reviews · 2026Review
- Development of Covalent Inhibitors of Chikungunya Virus nsP2 Cysteine Protease Enabled by Direct-to-Biology Synthesis and Screening.Journal of medicinal chemistry · 2026Article
- Analyzing Upper Extremity Disability From Health-Related Quality of Life in Chronic Chikungunya: A Biopsychosocial Approach.Journal of evaluation in clinical practice · 2026Observational
- Chikungunya waves in 2025 signal risk of endemicity in China.PLoS neglected tropical diseases · 2026Article
- Primary infection with a Brazilian chikungunya virus isolate protects immunocompetent mice against detectable viremia following homologous rechallenge.Archives of virology · 2026Article
- Chikungunya Vaccines in Travel Medicine: From Regulatory Approval to Real-World Challenges.Tropical medicine and infectious disease · 2026Review
- Cross-Family Mechanistic Analysis of Plant Alkaloids Against Neglected Arboviruses and Related RNA Viruses.Molecules (Basel, Switzerland) · 2026Review
- Retinoic acid is a translation inhibitor against chikungunya virus both in vitro and invivo.Virologica Sinica · 2026Article
123 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 8 institutions in 6 countries.
Funding
Abstract
Chikungunya virus is widespread throughout the tropics, where it causes recurrent outbreaks of chikungunya fever. In recent years, outbreaks have afflicted populations in East and Central Africa, South America and Southeast Asia. The virus is transmitted by Aedes aegypti and Aedes albopictus mosquitoes. Chikungunya fever is characterized by severe arthralgia and myalgia that can persist for years and have considerable detrimental effects on health, quality of life and economic productivity. The effects of climate change as well as increased globalization of commerce and travel have led to growth of the habitat of Aedes mosquitoes. As a result, increasing numbers of people will be at risk of chikungunya fever in the coming years. In the absence of specific antiviral treatments and with vaccines still in development, surveillance and vector control are essential to suppress re-emergence and epidemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.